Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort
2020 ◽
Vol 75
(11)
◽
pp. 253
2012 ◽
Vol 59
(13)
◽
pp. E1480
◽
2011 ◽
Vol 219
(1)
◽
pp. 291-297
◽
2004 ◽
Vol 44
(10)
◽
pp. 1996-2002
◽
2018 ◽
Vol 59
(5)
◽
pp. 293-295
◽